Firefly Bio
San Francisco
About Firefly Bio
Firefly Bio specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $94.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2024)
- Website: fireflybiologics.com
Industries & Categories
Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/firefly-bio-24613 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.